Logo image
How we approach thrombosis risk in children with COVID-19 infection and MIS-C
Journal article   Open access   Peer reviewed

How we approach thrombosis risk in children with COVID-19 infection and MIS-C

Anjali A. Sharathkumar, E. Vincent S. Faustino and Clifford M. Takemoto
Pediatric blood & cancer, Vol.68(7), pp.e29049-n/a
07/01/2021
DOI: 10.1002/pbc.29049
PMCID: PMC8206673
PMID: 33955167
url
https://doi.org/10.1002/pbc.29049View
Published (Version of record) Open Access

Abstract

Thrombosis within the microvasculature and medium to large vessels is a serious and common complication among critically ill individuals with coronavirus disease 2019 (COVID-19). While children are markedly less likely to develop severe disease than adults, they remain at risk for thrombosis during acute infection and with the post-acute inflammatory illness termed multisystem inflammatory syndrome in children. Significant knowledge deficits in understanding COVID-19-associated coagulopathy and thrombotic risk pose clinical challenges for pediatric providers who must incorporate expert opinion and personal experience to manage individual patients. We discuss clinical scenarios to provide framework for characterizing thrombosis risk and thromboprophylaxis in children with COVID-19.
Hematology Life Sciences & Biomedicine Oncology Pediatrics Science & Technology

Details

Logo image